✦ LIBER ✦

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes

✍ Scribed by Yuya Fujishima, Norikazu Maeda, Kana Inoue, Susumu Kashine, Hitoshi Nishizawa, Ayumu Hirata, Junji Kozawa, Tetsuyuki Yasuda, Kohei Okita, Akihisa Imagawa, Tohru Funahashi, Iichiro Shimomura

Book ID: 119900316
Publisher: BioMed Central
Year: 2012
Tongue: English
Weight: 351 KB
Volume: 11
Category: Article
ISSN: 1475-2840
DOI: 10.1186/1475-2840-11-107

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Beneficial effects of once-daily liraglu

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

✍ J.-P. Courrèges; T. Vilsbøll; M. Zdravkovic; T. Le-Thi; T. Krarup; O. Schmitz; R 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 370 KB

Improved glycaemic control with minimal

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes

✍ K. Kaku; M. F. Rasmussen; P. Clauson; Y. Seino 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 595 KB

Liraglutide, a once-daily human glucagon

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

✍ A. Garber; R. R. Henry; R. Ratner; P. Hale; C. T. Chang; B. Bode 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 971 KB

A review of efficacy and safety data reg

A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus

✍ Eduard Montanya; Giorgio Sesti 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 193 KB

Weight loss with liraglutide, a once-dai

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

✍ J. Jendle; M. A. Nauck; D. R. Matthews; A. Frid; K. Hermansen; M. Düring; M. Zdr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 579 KB